KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Capital Expenditures (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Capital Expenditures data on record, last reported at -$13.6 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 362.14% year-over-year to -$13.6 million; the TTM value through Dec 2025 reached $1.5 million, down 73.62%, while the annual FY2025 figure was $1.5 million, 73.62% down from the prior year.
  • Capital Expenditures reached -$13.6 million in Q4 2025 per PCRX's latest filing, down from $3.9 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $41.1 million in Q4 2021 and bottomed at -$13.6 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $4.9 million, with a median of $4.5 million recorded in 2022.
  • The widest YoY moves for Capital Expenditures: up 349366.67% in 2025, down 362.14% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $41.1 million in 2021, then crashed by 86.65% to $5.5 million in 2022, then crashed by 67.26% to $1.8 million in 2023, then crashed by 264.24% to -$3.0 million in 2024, then crashed by 362.14% to -$13.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$13.6 million in Q4 2025, $3.9 million in Q3 2025, and $10.5 million in Q2 2025.